February 25, 2013 | By Márcio Barra
Good news for people, like me, who are or might be allergic to cats’ fur. Today, Circassia Ltd, an allergy focused biotech, announced the results of a phase II study for their new ToleroMune® cat allergy therapy, a vacine comprised of seven peptides derived from Fel d 1, that quiets the T-cells reaction. And the results are promising for anyone who suffers allergic reactions to cats.
The phase II, parallel study conducted in 202 patients initially measured improvements in nasal and ocular allergy symptoms after treatment with ToleroMune® therapy or placebo. Then, two years after, and having received no further ToleroMune® treatment, 50 patients were called to be reevaluated after 4 days of exporsure to cat allergens. The results showed a 50.0% improvement on the Total Rhinoconjunctivitis Sympton Score (TRSS) vs 14.9% on placebo after exposure to the cat allergens, and a 38.3% TRSS improvement vs 13.4% on placebo during the four day cat allergen challenge. Overall symptoms were also reduced during the two years of no therapy.
ToleroMune® is currently being tested in phase III trials.
Read more at: Blogs.nature.com